Open Access

Update on the Pathogenic Mechanisms of Isocyanate-induced Asthma

  • Gyu-Young Hur1,
  • Sung-Jin Choi1,
  • Seung-Youp Shin2,
  • Sang-Ha Kim3 and
  • Hae-Sim Park1Email author
World Allergy Organization Journal20081:127

DOI: 10.1097/wox.0b013e3181625d8c

Received: 5 October 2007

Accepted: 12 November 2007

Published: 15 January 2008

Abstract

Background

The pathogenic mechanisms of toluene diisocyanate (TDI)-induced asthma are not understood clearly.

Methods

In this review, we summarized recent data to further understand the pathogenic mechanisms through recent approach of molecular genetic studies, and specific antibody responses to cellular mechanisms.

Results

Genetic polymorphism studies suggested the involvement of oxidant/antioxidant-related genes and neurogenic inflammatory response genes. A high-resolution technique of HLA allele suggested some HLA genetic markers presenting the phenotype of TDI-induced asthma. The new volatile type of TDI-human serum albumin conjugate could improve specific immunoglobulin E and immunoglobulin G bindings in enzyme-linked immunosorbent assay studies for identifying TDI-induced asthma patients. The role of bronchial epithelial cells and cytokeratins derived from epithelial cells could be involved in autoantibody productions, suggesting that an autoimmune mechanism may be involved in airway inflammation. Neutrophil activation and oxidant/antioxidant-related mechanisms were also suggested.

Conclusion

The pathogenic mechanism of TDI-induced asthma is complicated as various humoral and cellular mechanisms are combined and involved differently on an individual basis. Therefore, additional efforts for further elucidation should follow.

Keywords

asthma genetic polymorphism HLA specific IgE specific IgG toluene diisocyanate

Although more than 300 causative agents of asthma have been reported, isocyanate, especially toluene diisocyanate (TDI), is the most prevalent cause of occupational asthma worldwide. Although incidences are varied depending on the forms and types of isocyanate, it is generally reported that 5% of TDI-exposed workers could develop TDI-induced asthma [1]. The annual incidence rate of isocyanate-induced asthma was 1.8% in TDI production facilities [2]. The follow-up study on TDI-induced asthma demonstrated that 50% of TDI-induced asthmatic patients had experienced persistent asthmatic symptoms even after cessation of exposure to isocyanate [3]. The pathogenic mechanism of occupational asthma is complicated by the fact that both immunologic and non-immunologic pathways may be involved, depending upon the causative agent [36]. In addition, several environmental factors, including the nature of the causative agent and the level and mode of exposure, affect the pathogenesis of occupational asthma. In cases involving low-molecular-weight chemicals, particularly TDI, both immunoglobulin E (IgE)- and non-IgE-mediated pathways have been implicated [37]. Several studies examining the role of specific IgG antibodies against isocyanate have yielded controversial results [35]. This review summarizes our current understanding of the pathogenic mechanisms of TDI-induced asthma and outlines a series of questions that must be addressed to further our understanding of the pathogenesis of isocyanate-induced asthma.

Genetic mechanisms of isocyanate-induced asthma

HLA allele studies

A European study of 142 patients with TDI-induced asthma and 50 asymptomatic exposed controls demonstrated that HLA class I alleles were not significantly associated with TDI-induced asthma [8]. However, a comparison of TDI-induced asthma subjects with asymptomatic exposed controls using high-resolution techniques demonstrated that 1 HLA class II allele, DQB1*0503, and 1 haplotype, DQB1*0201-0301, were significantly associated with TDI-induced asthma [9, 10]. These results were later refuted by data from a German population, showing no association between the disease and the HLA class II allele [11]. In a Korean population, we used a high-resolution sequencing method to compare a number of HLA class I and II alleles in 55 TDI-induced asthma patients with those in 47 asymptomatic exposed subjects and 95 unexposed healthy nonatopic controls; the HLA haplotype DRB1*15-DPB1*05 was found to be a susceptibility marker for the development of TDI-induced asthma among exposed workers [12]. To resolve the differences between our results and those of the other groups mentioned previously, additional studies using a larger cohort of TDI-induced asthma patients in different ethnic groups are needed.

Genetic polymorphism studies

The genes for glutathione S-transferase [13] and N-acetyltransferase [14] are believed to confer susceptibility to, or protection against, TDI-associated asthma. Bernstein et al [15] suggested a gene-to-environment interaction with IL4RA, CD14, and IL13. Based on studies showing the involvement of neurogenic inflammation in TDI-induced asthma, we used a single base extension to screen for 2 single-nucleotide polymorphism of neurokinin 2 receptor (NK2R) gene, 7853C > T and 11424G > A, in 70 patients with TDI-induced occupational asthma, 59 asymptomatic exposed controls, and 93 unexposed healthy controls [16]. No significant differences were noted in the allele, genotype, or haplotype frequencies of the 2 single-nucleotide polymorphism among the 3 groups. However, those TDI-exposed workers with the NK2R 7853CC genotype had higher serum levels of vascular endothelial growth factor than did those with the CT or TT genotype. We speculate that the NK2R 7853CC genotype may contribute to an increase in the serum level of vascular endothelial growth factor, resulting in airway inflammation after exposure to TDI. Additional studies are needed to investigate other candidate genes and gene-to-environment interactions in people of various ethnicities.

Role of specific IgE antibodies against isocyanate in occupational asthma

Several investigators have detected IgE antibodies specific for TDI-human serum albumin (HSA) conjugate in the sera of workers showing a positive bronchial challenge response to TDI, with a reported prevalence of 0% to 50% of workers [3, 4, 7]. Maestrelli et al [17] demonstrated that the bronchial mucosa of TDI-induced asthma patients contained increased numbers of cells expressing interleukin 5 (IL-5) and IL-4. Similarly, we found that 13% of TDI-induced asthma patients had specific IgE antibodies, [18] although subsequent enzyme-linked immunosorbent assay (ELISA) inhibition tests using 3 different TDI-HSA conjugates prepared under the same conditions revealed different inhibition patterns [19]. We recently demonstrated that the sensitivity of the specific IgE antibodies could be increased to 44% when a volatile type of TDI-HSA conjugate was used instead of a conventional liquid conjugate, [20] indicating that antigen quality affects the ability to detect specific antibodies. As shown in Table 1, the prevalence of specific IgE antibodies varied according to the antigen used and the population studied. These findings suggest that IgE bindings to the antigenic determinant of the TDI-HAS conjugate can differ from 1 individual to another; thus, if we improve the TDI-protein conjugate further, we should be able to identify additional specific antibodies. This may explain the variable results obtained in prevalence studies of serum-specific IgE antibodies against TDI-HSA conjugate in patients with TDI-induced asthma.
Table 1

Determination of Specific IgE and IgG Antibodies in Subjects With Isocyanate-induced Asthma

  

Specific

IgE (%)

Specific

IgG (%)

Authors (yr)

Assay

Se

Sp

Se

Sp

Butcher BT et al (1980) [42]

RAST

19

--

--

--

Pezzini A et al (1984) [43]

RAST

39

--

--

--

Keskinen H et al (1988) [44]

RAST

20

--

--

--

Cartier A et al (1989) [21]

ELISA

31

97

72

76

Karol MH et al (1994) [45]

RAST

3

93

3

93

Tee RD et al (1998) [7]

RAST ratio > 2

28

92

--

--

 

RAST ratio > 3

20

100

--

--

Park HS et al (1999) [18]

ELISA

14

92

46

92

Bernstein DI et al (2002) [28]

ELISA

21

89

47

74

Ye YM et al (2006) [20]

ELISA

43.9

--

30.3

--

RAST indicates radioallergosorbent test; ELISA, enzyme-linked immunosorbent assay; Se, sensitivity; Sp, specificity.

Thus, it is certain that IgE-mediated responses contribute to the development of asthmatic symptoms in TDI-induced asthmatic patients; however, additional studies are needed to develop a more effective TDI-HSA conjugate and to investigate the role of non-IgE-mediated mechanisms.

Pathogenic role of specific IgG antibodies

A few studies have suggested that specific IgG antibodies against hexamethylene diisocyanate (HDI)-HSA and methylene diphenyl diisocyanate (MDI)-HSA conjugates play a pathogenic role in occupational asthma based on an association between IgG antibodies and the results of bronchoprovocation tests (BPTs), [21] whereas other investigators have suggested that specific IgG antibodies against MDI are merely indicators of MDI exposure [22]. We also reported the prevalence of serum-specific IgG antibodies against TDI-HSA conjugates [18]. The serum level of specific IgG antibodies was significantly higher in subjects showing a positive response in a TDI-BPT (46%) compared with subjects exhibiting a negative TDI-BPT response (7.7%), subjects with allergic asthma (0%), and unexposed healthy controls (0%). The prevalence of specific IgG did not depend significantly upon the type of asthmatic response, the presence of specific IgE antibodies against TDI-HSA conjugate, or atopic status. Given these data, the presence of IgG antibodies against TDI-HSA conjugate may indicate exposure to TDI and may be associated with a patient's TDI-BPT results.

The cellular immune response

Inflammatory reactions involving eosinophils, mast cells, and T lymphocytes, especially those bearing IL-2 receptors, [17, 23] and increased cytokine production by Th2 cells occur in the bronchial mucosae of patients with TDI-induced asthma, as in patients with allergic asthma. Other immune responses to diisocyanate-related asthma include lymphoproliferative responses and cytokine/chemokine production with exposure to isocyanate [24, 25]. Immunohistochemical finding comparing the bronchial mucosa between patients with TDI-induced asthma and those with allergic asthma has revealed significantly higher numbers of mast cells and neutrophils in patients with TDI-induced asthma but no significant difference in the number of T cells [26]. A significant correlation was also found between the numbers of neutrophils and mast cells. With regard to T-cell cytokine secretion, interferon-γ production was observed in both peripheral mononuclear cells and T-cell lines collected from subjects newly diagnosed as having TDI-induced asthma [24]. A few studies have demonstrated the role of CD8+ T lymphocytes in the airway mucosa of patients with TDI-induced asthma, and a specific T-cell line was successfully derived from T cells in the airway mucosa of a patient with TDI-induced asthma [27]. In addition, it was shown that isocyanate-induced monocyte chemoattractant protein-1 (MCP-1) production by peripheral blood mononuclear cells may be used to differentiate between isocyanate-induced asthma patients and asymptomatic exposed controls [25, 28]. These data suggest that Th2 lymphocytes and other inflammatory cells, such as eosinophils, mast cells, and activated neutrophils, may contribute to the development of TDI-induced bronchoconstriction. A role of CD8+ T lymphocytes was suggested.

Epithelial cells and autoimmune mechanisms

Mounting evidence suggests that diisocyanates are able to bind airway epithelial cell proteins, resulting in airway inflammation with cytokine and chemokine production and cellular recruitment [29]. The toxicity of diisocyanates toward airway epithelial tissues has also been reported, and MDI and HDI prepolymers were shown to induce airway epithelial barrier dysfunction that was partly associated with altered glutamine levels [30, 31]. The effect of TDI on the expression of lung cytokine P450 enzymes has also been documented [32]. We attempted to culture human bronchial epithelial cells, Beas-2B, with TDI-HSA conjugates to identify the source of the IL-8 detected in the sputum of TDI-induced asthma patients [33]. The production of IL-8 and regulated upon activation in normal T cell expressed, and secreted (RANTES) was significantly increased in a dose-dependent manner after exposure to a peripheral mononuclear cell culture supernatant derived from a TDI-induced asthma patient, and this effect was suggested to be mediated by epidermal growth factor receptor and p38 mitogen-activated protein [34].

Recent microarray analyses of epithelioid cells demonstrated increased expression of cytokeratin (CK) 19 in cultured bronchial epithelial cells after TDI exposure. The prevalence of serum IgGs against CK-19 was significantly higher in TDI-induced asthma patients than in asymptomatic exposed controls or normal controls, [35] and the degree of airway hyperresponsiveness to methacholine was more severe in patients with serum CK-specific IgG [36]. The CKs are normally located in the intracellular space, but may be able to access the immune system upon epithelial damage or cell death. The precise mechanism of their production is unknown, although several studies have suggested that CKs are solubilized by proteolysis during apoptosis and can subsequently enter the circulation, where they may stimulate the formation of new antibodies. These findings indicate that among patients with TDI-induced asthma, those who are most susceptible to epithelial damage by TDI exposure may develop CK-specific IgGs.

Neutrophil activation and oxidant/antioxidant mechanisms

The bronchoalveolar lavage fluid of isocyanate-induced asthma patients, especially those with latent asthmatic responses, showed neutrophilia [37]. The number of neutrophils was significantly higher in the bronchial mucosa of TDI-induced asthma patients than in allergic asthma patients in our study [26]. The myeloperoxidase level, a neutrophil activation marker, was increased in the airway secretions of TDI-induced asthma patients after TDI challenge, and this increase was accompanied by an increase in IL-8 and leukotriene B4 production [38, 39]. This suggests that the release of IL-8 and leukotriene B4 after exposure to TDI contributes to neutrophilic infiltration into the airway mucosa of patients with TDI-induced asthma.

A remarkable increase in exhaled nitric oxide was detected after exposure to isocyanate in TDI-induced asthma patients [40]. Reduced levels of antioxidants were detected in the bronchial epithelial cells of patients exposed to TDI [41]. Considering the critical role of neutrophils in oxidant-induced injury in the asthmatic airway, oxidant/antioxidant-induced inflammation caused by activated neutrophils combined with reduced antioxidant content in the airway mucosa may contribute to the pathogenesis of TDI-induced asthma.

Perspectives

Recent studies demonstrate that the pathogenic mechanism of TDI-induced asthma is complicated as various humoral and cellular mechanisms are combined and involved differently on an individual basis. More efforts should be devoted to increase the sensitivity of specific antibody detection techniques with a better TDI-HSA conjugate, and to study the cellular and molecular genetic mechanisms.

Notes

Supported by a grant from the Korean Health 21 R&D Project, Ministry of Health and Welfare, R.O.K. (A 050571).

Authors’ Affiliations

(1)
Department of Allergy and Rheumatology, Ajou University School of Medicine
(2)
Department of Otolaryngology, College of Medicine, KyungHee University
(3)
Department of Internal Medicine, Yonsei University Wonju College of Medicine

References

  1. Diem JE, Jones RN, Hendrick DJ, et al: Five-year longitudinal study of workers employed in a new toluene diisocyanate manufacturing plant. Am Rev Respir Dis. 1982, 126: 420-428.PubMedGoogle Scholar
  2. Ott MG, Klees JE, Poche SL: Respiratory health surveillance in a toluene di-socyanate production unit, 1967-97: clinical observations and lung function analyses. Occup Environ Med. 2000, 57: 43-52. 10.1136/oem.57.1.43.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Park HS, Cho SH, Hong CS, Kim YY: Isocyanate induced occupational asthma in far-east Asia: pathogenesis to prognosis. Clin Exp Allergy. 2002, 32: 198-204. 10.1046/j.1365-2222.2002.01290.x.View ArticlePubMedGoogle Scholar
  4. Sastre J, Vandenplas O, Park HS: Pathogenesis of occupational asthma. Eur Respir J. 2003, 22: 364-373. 10.1183/09031936.03.00045103.View ArticlePubMedGoogle Scholar
  5. Boulet LP, Lemiere C, Gautrin D, et al: New insights into occupational asthma. Curr Opin Allergy Clin Immunol. 2007, 7: 96-101.View ArticlePubMedGoogle Scholar
  6. Jones MG, Floyd A, Nouri-Aria KT, Jacobson MR, Druham SR, Taylor AN, Cullinan P: Is occupational asthma to diisocyanates a non-IgE-mediated disease?. J Allergy Clin Immunol. 2006, 117: 663-669. 10.1016/j.jaci.2005.09.053.View ArticlePubMedGoogle Scholar
  7. Tee RD, Cullinan P, Welch J, Buige PS, Newman-Taylor AJ: Specific IgE to isocyanates: a useful diagnostic role in occupational asthma. J Allergy Clin Immunol. 1998, 101: 709-715. 10.1016/S0091-6749(98)70181-2.View ArticlePubMedGoogle Scholar
  8. Beghé B, Padoan M, Moss CT, et al: Lack of association of HLA class I genes and TNF alpha-308 polymorphism in toluene diisocyanate-induced asthma. Allergy. 2004, 59: 61-64.View ArticlePubMedGoogle Scholar
  9. Taylor AN: Role of human leukocyte antigen phenotype and exposure in development of occupational asthma. Curr Opin Allergy Clin Immunol. 2001, 1: 157-161.View ArticlePubMedGoogle Scholar
  10. Bignon JS, Aron Y, Ju LY, et al: HLA class II alleles in isocyanate-induced asthma. Am J Respir Crit Care Med. 1994, 149: 71-75. 10.1164/ajrccm.149.1.8111601.View ArticlePubMedGoogle Scholar
  11. Rihs HP, Barbalho-Krolls T, Huber H, Baur X: No evidence for the influence of HLA class II in alleles in isocyanate-induced asthma. Am J Int Med. 1997, 32: 522-527. 10.1002/(SICI)1097-0274(199711)32:5<522::AID-AJIM13>3.0.CO;2-4.View ArticleGoogle Scholar
  12. Kim SH, Oh HB, Lee KW, et al: HLA DRB1*15-DPB1*05 haplotype: a susceptible gene marker for isocyanate-induced occupational asthma?. Allergy. 2006, 61: 891-894. 10.1111/j.1398-9995.2006.01023.x.View ArticlePubMedGoogle Scholar
  13. Mapp CE, Fryer AA, Marzo ND, et al: Glutathione S-transferase GSTP1 is a susceptibility gene for occupational asthma induced by isocyanates. J Allergy Clin Immunol. 2002, 109: 867-872. 10.1067/mai.2002.123234.View ArticlePubMedGoogle Scholar
  14. Wikman H, Piirila P, Rosenberg C, et al: N-acetyl transferase genotypes as modifiers of diisocyanate exposure-associated asthma risk. Pharmacogenetics. 2002, 12: 227-233. 10.1097/00008571-200204000-00007.View ArticlePubMedGoogle Scholar
  15. Bernstein DI, Wang N, Campo P, et al: Diisocyanate asthma and gene-environment interactions with IL4RA, CD-14, and IL-13 genes. Allergy Asthma Immunol. 2006, 97: 800-806. 10.1016/S1081-1206(10)60972-6.View ArticleGoogle Scholar
  16. Ye YM, Kang YM, Kim SH, et al: Relationship between neurokinin 2 receptor gene polymorphisms and serum vascular endothelial growth factor levels in patients with toluene diisocyanate-induced asthma. Clin Exp Allergy. 2006, 36: 1153-1160. 10.1111/j.1365-2222.2006.02547.x.View ArticlePubMedGoogle Scholar
  17. Maestrelli P, Occari P, Turato G, et al: Expression of interleukin (IL)-4 and IL-5 proteins in asthma induced by toluene diisocyanate (TDI). Clin Exp Allergy. 1997, 27: 1292-1298. 10.1111/j.1365-2222.1997.tb01174.x.View ArticlePubMedGoogle Scholar
  18. Park HS, Kim HY, Nahm DH, Son JW, Kim YY: Specific IgG, but not specific IgE, antibodies to toluene diisocyanate-human serum albumin conjugate are associated with toluene diisocyanate bronchoprovocation test results. J Allergy Clin Immunol. 1999, 104: 847-851. 10.1016/S0091-6749(99)70297-6.View ArticlePubMedGoogle Scholar
  19. Park HS, Kim HY, Suh JH, Nahm DH, Kim SS, Lee SK: Diverse profiles of specific IgE response to toluene diisocyanate (TDI)-human serum albumin (HSA) conjugate in TDI-induced asthma patients. J Korean Med Sci. 2000, 16: 57-61.View ArticleGoogle Scholar
  20. Ye YM, Kim CW, Kim HR, et al: Biophysical determinants of toluene diisocyanate antigenicity associated with exposure and asthma. J Allergy Clin Immunol. 2006, 118: 885-891. 10.1016/j.jaci.2006.06.026.View ArticlePubMedGoogle Scholar
  21. Cartier A, Grammer L, Malo JL, Lagier F, Ghezzo H, Harris K, Patterson R: Specific serum antibodies against isocyanate: association with occupational asthma. J Allergy Clin Immunol. 1989, 84: 507-514. 10.1016/0091-6749(89)90364-3.View ArticlePubMedGoogle Scholar
  22. Lushniak BD, Reh CM, Bernstein DI, Gallagher JS: Indirect assessment of 4,4'-diphenylmehane diisocyanate (MDI) exposure by evaluation of specific humoral immune responses to MDI conjugated to human serum albumin. Am J Ind Med. 1998, 33: 471-477. 10.1002/(SICI)1097-0274(199805)33:5<471::AID-AJIM6>3.0.CO;2-V.View ArticlePubMedGoogle Scholar
  23. Bentley AM, Maestrelli P, Saetta M, et al: Activated T-lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced asthma. J Allergy Clin Immunol. 1992, 89: 821-828. 10.1016/0091-6749(92)90437-7.View ArticlePubMedGoogle Scholar
  24. Lee M, Park S, Park HS, Yoon JK: Cytokine secretion pattern of T cells responding to haptenized-human serum albumin in toluene diisocyanate-induced asthma patients. J Korean Med Sci. 1998, 13: 459-465.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Lummus ZL, Alam R, Bernstein JA, Bernstein DI: Diisocyanate antigen-enhanced production of monocyte chemoattractant protein-1, IL-8, and tumor necrosis factor-alpha by peripheral mononuclear cells of workers with occupational asthma. J Allergy Clin Immunol. 1998, 102: 265-274. 10.1016/S0091-6749(98)70095-8.View ArticlePubMedGoogle Scholar
  26. Park HS, Hwang SC, Nahm DH, Yim HE: Immunohistochemical characterization of cellular infiltrate in airway mucosa of toluene diisocyanate-induced asthma. J Korean Med Sci. 1998, 13: 12-16.Google Scholar
  27. Del Prete GF, De Carli M, D'Elios MM, Maestrelli P, Ricci M, Fabbri L, Romagnani S: Allergen exposure induces the activation of allergen-specific Th2 cells in the airway mucosa of patients with allergic respiratory disorders. Eur J Immunol. 1993, 23: 1445-1449. 10.1002/eji.1830230707.View ArticlePubMedGoogle Scholar
  28. Bernstein DI, Cartier A, Cote J, et al: Diisocyanate antigen-stimulated monocyte chemoattractant protein-1 synthesis has greater test efficiency than specific antibodies for identification of diisocyanate asthma. Am J Respir Crit Care Med. 2002, 166: 445-450. 10.1164/rccm.2109018.View ArticlePubMedGoogle Scholar
  29. Wisnewski AV, Redlich CA: Recent developments in diisocyanate asthma. Curr Opin Allergy Clin Immunol. 2001, 1: 169-175.View ArticlePubMedGoogle Scholar
  30. Pauluhn J: Inhalation toxicity of 1,6-hexamethylene diisocyanate homopolymer (HDI-IC) aerosol: results of single inhalation exposure studies. Toxicol Sci. 2000, 58: 173-187. 10.1093/toxsci/58.1.173.View ArticlePubMedGoogle Scholar
  31. Pauluhn J: Acute inhalation toxicity of polymeric diphenyl-methane 4,4'-diisocyanate in rats: time course of changes in bronchoalveolar lavage. Arch Toxicol. 2000, 74: 257-269. 10.1007/s002040000114.View ArticlePubMedGoogle Scholar
  32. Pons F, Haag M, Corcos L, Bonnet P, Guillouzo A, Lugnier A, Frossard N: Inhalation of toluene diisocyanate affects cytochrome P450 2B1 expression rat lung. Arch Toxicol. 2000, 74: 397-403. 10.1007/s002040000153.View ArticlePubMedGoogle Scholar
  33. Lee YM, Kim HA, Park HS, Lee SK, Nahm DH: Exposure to toluene diisocyanate induces IL-8 production from bronchial epithelial cells: effect of pro-inflammatory cytokines. J Korean Med Sci. 2003, 18: 803-812.Google Scholar
  34. Ogawa H, Inoue S, Ogushi F, Ogura H, Nakamura Y: Toluene diisocyanate (TDI) induces production of inflammatory cytokines and chemokines by bronchial epithelial cells via the epidermal growth factor receptor and p38 mitogen-activated protein kinase pathways. Exp Lung Res. 2006, 32: 245-262. 10.1080/01902140600817515.View ArticlePubMedGoogle Scholar
  35. Choi JH, Nahm DH, Kim SH, Kim YS, Suh CH, Park HS, Ahn SW: Increased levels of IgG to cytokeratin 19 in sera of patients with toluene diisocyanate-induced asthma. Ann Allergy Asthma Immunol. 2004, 93: 293-298. 10.1016/S1081-1206(10)61504-9.View ArticlePubMedGoogle Scholar
  36. Ye YM, Nahm DH, Kim CW, et al: Cytokeratin autoantibodies: useful serologic markers for toluene diisocyanate-induced asthma. Yonsei Med J. 2006, 47: 773-781. 10.3349/ymj.2006.47.6.773.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Fabbri LM, Boschetto P, Zocca E, et al: Bronchoalveolar neutrophilia during late asthmatic reactions induced by toluene diisocyanate. Am Rev Respir Dis. 1987, 136: 36-42. 10.1164/ajrccm/136.1.36.View ArticlePubMedGoogle Scholar
  38. Park HS, Jung KS, Kim HM, Nahm DH, Kang KR: Neutrophil activation following TDI bronchial challenges to the airway secretion from subjects with TDI-induced asthma. Clin Exp Allergy. 1999, 29: 1395-1401. 10.1046/j.1365-2222.1999.00682.x.View ArticlePubMedGoogle Scholar
  39. Lemiere C, Pelissier S, Tremblay C, Chaboillez S, Thivierge M, Stankova J, Rola-Pleszczynski M: Leukotrienes and isocyanate-induced asthma: a pilot study. Clin Exp Allergy. 2004, 34: 1684-1689. 10.1111/j.1365-2222.2004.02102.x.View ArticlePubMedGoogle Scholar
  40. Barbinova L, Baur X: Increase in exhaled nitric oxide after work-related isocyanate exposure. Int Arch Occup Environ Health. 2006, 79: 387-395. 10.1007/s00420-005-0051-x.View ArticlePubMedGoogle Scholar
  41. Lange RW, Day BW, Lemus R, Tyurin VA, Kagan VE, Karol MH: Intracellular S-glutathionyl adducts in murine lung and human bronchoepithelial cells after exposure to diisocyanatotoluene. Chem Res Toxicol. 1999, 12: 931-936. 10.1021/tx990045h.View ArticlePubMedGoogle Scholar
  42. Butcher BT, O'Neil CE, Reed MA, Salvaggio JE: Radioallergosorbent testing of toluene diisocyanate-reactive individuals using p-tolyl isocyanate antigen. J Allergy Clin Immunol. 1980, 66: 213-216. 10.1016/0091-6749(80)90041-X.View ArticlePubMedGoogle Scholar
  43. Pezzini A, Riviera A, Paggiaro P, et al: Specific IgE antibodies in twenty eight workers with diisocyanate induced bronchial asthma. Clin Allergy. 1984, 14: 453-461. 10.1111/j.1365-2222.1984.tb02229.x.View ArticlePubMedGoogle Scholar
  44. Keskinen H, Tupasela O, Tiikkainen U, Nordman H: Experiences of specific IgE in asthma due to diisocyanates. Clin Allergy. 1988, 18: 597-604. 10.1111/j.1365-2222.1988.tb02911.x.View ArticlePubMedGoogle Scholar
  45. Karol MH, Tollerud DJ, Campbell TP, Fabbri L, Maestrelli P, Saetta M, Mapp CE: Predictive value of airways hyperresponsiveness and circulating IgE for identifying types of responses to toluene diisocyanate inhalation challenge. Am J Respir Crit Care Med. 1994, 149: 611-615. 10.1164/ajrccm.149.3.8118626.View ArticlePubMedGoogle Scholar

Copyright

© World Allergy Organization; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.